Editorial Commentary: The Dawning of Microbiome Remediation for Addressing Antibiotic Resistance

Clinical Infectious Diseases

Volumn 62, Issue 12, 2016, Pages 1487-1488

  Halpin, Alison Laufer ^a   McDonald, L Clifford ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

fecal microbiota transplantation; microbiome; resistome

Indexed keywords

ANTIBIOTIC AGENT; PROBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; COLONOSCOPY; ESCHERICHIA COLI; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION CONTROL; INTESTINE FLORA; KLEBSIELLA PNEUMONIAE; METAGENOMICS; MICROBIOME; NOTE; PRIORITY JOURNAL; MICROFLORA;

DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIOTA;

EID: 84973484058     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw187     Document Type: Note

References (15)

1. CDC. Antibitoic resistance threats in the United States. Available at: http://www.cdc.gov/drugresistance/threatreport-2013. Accessed 10 April 2016.
2. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008; 6:e280.
3. Power SE, O'Toole PW, Stanton C, Ross RP, Fitzgerald GF. Intestinal microbiota, diet and health. Br J Nutr 2014; 111:387-402.
4. Raymond F, Ouameur AA, DeraspeM, et al. The initial state of the human gut microbiome determines its reshaping by antibiotics. ISME J 2016; 10:707-20.
5. Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012; 55:905-14.
6. Yu LC, Shih YA, Wu LL, et al. Enteric dysbiosis promotes antibiotic-resistant bacterial infection: systemic dissemination of resistant and commensal bacteria through epithelial transcytosis. Am J Physiol Gastrointest Liver Physiol 2014; 307: G824-35.
7. Halpin AL, de Man T, Kraft C, et al. Intestinal microbiome disruption in patients in a longterm acute care hospital: A case for development of microbiome disruption indices to improve infection prevention. Am J Infect Control 2016. Available at: http://www.sciencedirect.com/science/ article/pii/S0196655316000407. Accessed 10 April 2016.
8. Friedman-Moraco RJ, Mehta AK, Lyon GM, Kraft CS. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am J Transplant 2014; 14:477-80.
9. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825-34.
10. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-15.
11. Crum-Cianflone NF, Sullivan E, Ballon-Landa G. Fecal microbiota transplantation and successful resolution of multidrug-resistant-organism colonization. J Clin Microbiol 2015; 53:1986-9.
12. Singh R, van Nood E, Nieuwdorp M, et al. Donor feces infusion for eradication of Extended Spectrum beta-Lactamase producing Escherichia coli in a patient with end stage renal disease. Clin Microbiol Infect 2014; 20:O977-8.
13. Borody T, Fischer M, Mitchell S, Campbell J. Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead. Expert Rev Gastroenterol Hepatol 2015; 9:1379-91.
14. Tosh PK, McDonald LC. Infection control in the multidrug-resistant era: tending the human microbiome. Clin Infect Dis 2012; 54:707-13.
15. Khanna S, Pardi DS, Kelly CR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis 2016. Available at: http://jid. oxfordjournals.org/content/early/2016/02/04/ infdis.jiv766.full.pdf+html. Accessed 10 April 2016.